// App-Quantinova.ai

: A study to determine enzalutamide long term safety and efficacy for men with castration-resistant prostate cancer: A multicenter, prospective DELC study.

Researchers

Presenter

  • Koji Hatano

Principal Investigators

  • Akira Nagahara

  • Wataru Nakata

  • Mototaka Sato

  • Tetsuya Takao

  • Soichi Matsumura

  • Kensaku Nishimura

  • Shingo Takada

  • Toshichika Iwanishi

  • Yasuyuki Kobayashi

  • Yu Ishizuya

  • Tsuyoshi Takada

  • Koichi Okada

  • Hitoshi Inoue

  • Motohide Uemura

  • Norio Nonomura

Medical Centers

  • Toyonaka Municipal Hospital, Toyonaka, Japan

  • Osaka University Medical School, Suita, Japan

  • Higashiosaka City Medical Center, Higashiosaka, Japan

  • Osaka Rousai Hospital, Osaka, Japan

  • Osaka General Medical Center, Osaka, Japan

  • Kinki Central Hospital Itami, Itami, Japan

  • Hyogo Prefectual Nishinomiya Hospital, Nishinomiya, Japan

  • Minoh City Hospital, Minoh, Japan

Locations

  • Japan

Companies

  • N/A

Study Components

Therapeutic Area

  • Nephrology

  • Oncology (ONC)

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • Prostate specific antigen

Drug/Treatment

  • Enzalutamide

  • Bicalutamide

  • Flutamide

  • Androgen Tear

Outcome

  • N/A

Study Design

  • Observational

  • Multicenteric

  • Prospective

Phase

  • NA

Study Id's

  • UMIN000019855

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved